

Advanced Personalized Orthopedic Implants Using Three-Dimensional Bioprinting Technologies

Chinedu Michael Okafor [1*], Amina Zainab Bello [2]
[1] Department of Pharmaceutical Nanotechnology and Drug Delivery Research, University of Lagos, Nigeria
[2] Center for Translational Nanomedicine and Precision Therapeutics, Ahmadu Bello University, Nigeria

* Corresponding Author: **Chinedu Michael Okafor**

Article Info

ISSN (Online): 3107-6629
Volume: 01
Issue: 06
November – December 2025
Received: 08-09-2025
Accepted: 10-10-2025
Published: 05-11-2025
Page No: 04-08

Abstract
Background: The fabrication of standard-sized orthopedic implants often results in suboptimal anatomical fit, prolonged surgical times, and elevated revision rates. Three-dimensional (3D) bioprinting has emerged as a disruptive platform capable of producing patient-specific implants with precise geometric fidelity, tunable porosity, and enhanced biological integration.
Objective: To evaluate the clinical performance, biomaterial properties, and workflow efficiency of personalized 3D-bioprinted orthopedic implants compared to conventional manufacturing approaches.
Methods: A comparative analysis was conducted across six bioprinting technologies, evaluating resolution, compatible biomaterials, and fabrication constraints. Clinical outcome data from 480 patients over a 60-month follow-up were analysed for osseointegration, implant survival, pain scores, and revision rates.
Results: 3D-printed implants demonstrated an 83.3% improvement in anatomical fit accuracy (0.3 vs. 1.8 mm deviation), a 23.3% increase in osseointegration rate (91.5% vs. 74.2%), and a 59.6% reduction in revision surgery rate compared to conventional implants ($p < 0.001$).
Conclusion: 3D bioprinting offers transformative clinical advantages for orthopedic implantology. Standardisation of bioink formulations, regulatory alignment, and cost reduction are key prerequisites for broad clinical adoption.

DOI: https://doi.org/10.54660/IJOOR.2025.1.6.04-08

Keywords: 3D bioprinting, Orthopedic implants, Personalized implants, Biomaterials, Osseointegration, Implant survival, Revision surgery rate

1. Introduction

Orthopedic surgery confronts a fundamental anatomical challenge: the human skeleton is highly variable across individuals in size, curvature, density, and cortical thickness. Conventional implant manufacturing—relying on standardised catalogue sizes—cannot adequately address this variability, resulting in geometric mismatch, stress-shielding, micromotion, and elevated failure rates [1, 2]. The clinical consequences include prolonged rehabilitation, higher revision surgery burden, and diminished patient-reported outcomes.

Three-dimensional bioprinting, broadly defined as the additive layer-by-layer deposition of biomaterials to produce three-dimensional constructs, represents a paradigm shift in implant fabrication. By integrating patient-specific imaging data with computer-aided design and advanced biomaterials, bioprinting enables the production of implants with millimetre-level anatomical precision, controlled porosity for osseointegration, and—increasingly—the capacity to incorporate living cells and growth factors directly into the construct [3–6].

Since its introduction into the biomedical domain in the early 2000s, 3D bioprinting has diversified into six major technological

platforms, each with distinct resolution capabilities, compatible biomaterials, and clinical trade-offs [7–9]. Simultaneously, the biomaterials palette has expanded from thermoplastic polymers to titanium alloys, ceramic composites, and cell-laden hydrogel bioinks. This article provides a structured evaluation of these technologies and biomaterials, presents a personalised implant workflow, and critically analyses clinical performance data relative to conventional implants.

2. Related Work

Early applications of additive manufacturing in orthopedics were confined to pre-surgical planning models and intraoperative guides, fabricated predominantly via fused deposition modeling (FDM) using polylactic acid (PLA) or acrylonitrile butadiene styrene (ABS) [10, 11]. The transition to implantable constructs demanded biomaterials with biocompatibility certification, mechanical performance comparable to cortical bone (15–25 GPa elastic modulus), and surface chemistry conducive to osteoblast adhesion [12, 13]. Selective laser sintering (SLS) and electron beam melting (EBM) of titanium alloy Ti-6Al-4V introduced porous metallic implants with trabecular-mimicking architectures, enhancing osseointegration through mechanical interlocking and surface area amplification [14–16]. Concurrently, hydroxyapatite (HA) and tricalcium phosphate (TCP) ceramic scaffolds fabricated via binder jetting demonstrated osteoconductivity and resorbable properties, supporting gradual bone ingrowth and load transfer [17, 18].

The advent of extrusion-based bioprinting enabled the incorporation of living chondrocytes and mesenchymal stem cells within hydrogel matrices, opening avenues for osteochondral interface repair [19, 20]. Kang *et al*. demonstrated the first human-scale integrated tissue construct using integrated tissue-organ printer (ITOP) technology, combining PCL with cell-laden hydrogels [12]. Despite this progress, translational barriers—including scaffold vascularisation, long-term cell viability, and regulatory classification—continue to constrain clinical deployment of fully bioprinted living implants [21–23].

3. Bioprinting Technologies for Orthopedic Implants

Six major bioprinting platforms are currently employed or under clinical investigation for orthopedic applications. Fused deposition modeling (FDM) extrudes thermoplastic filaments such as polycaprolactone (PCL) and polyether ether ketone (PEEK) through a heated nozzle, producing mechanically robust scaffolds suited to load-bearing applications. Its accessibility and scalability are offset by limited resolution and the inability to process cell-laden bioinks without thermal compromise [9, 10].

Stereolithography (SLA) and digital light processing (DLP) cure photosensitive resins with ultraviolet or visible light, achieving the highest spatial resolution (25–100 micrometres) among bioprinting technologies. GelMA-based hydrogels processed via SLA support chondrocyte-laden constructs with high architectural fidelity [5, 7]. Selective laser sintering (SLS) offers strong mechanical properties and eliminates the need for support structures, making it ideal for complex porous titanium and ceramic geometries, although elevated processing temperatures preclude cell encapsulation [16, 17].

Inkjet and extrusion-based bioprinting represent the primary cell-compatible platforms. Inkjet systems deposit picoliter droplets of low-viscosity bioink, enabling precise cellular patterning with high viability [19]. Extrusion bioprinting, the most widely adopted modality, accommodates a broader viscosity range and enables co-deposition of structural polymers and biological matrices. Laser-induced forward transfer (LIFT) offers nozzle-free deposition with exceptional resolution but remains constrained to research applications due to system complexity [22, 23]. Table 1 provides a comparative summary.

Table 1: Comparison of 3D Bioprinting Technologies for Orthopedic Applications

Technology	Resolution	Biomaterials	Advantages	Limitations
Fused Deposition Modeling (FDM)	100–300 µm	PLA, PCL, PEEK	Low cost, scalable, easy post-processing	Limited resolution, thermal stress on cells
Stereolithography (SLA)	25–100 µm	Photo-resins, GelMA	High precision, smooth surface finish	UV cytotoxicity, resin biocompatibility concerns
Selective Laser Sintering (SLS)	50–150 µm	HA, TCP, Nylon	No support structures, strong mechanical properties	High temperature limits cell encapsulation
Inkjet Bioprinting	20–100 µm	Alginate, fibrin hydrogels	Cell-compatible, fast deposition	Low viscosity restriction, nozzle clogging risk
Extrusion Bioprinting	150–400 µm	Collagen, bioinks, PCL	Wide material compatibility, scalable	Lower resolution, shear stress on cells
Laser-Induced Forward Transfer (LIFT)	10–50 µm	Bioinks, living cells	Nozzle-free, high cell viability	Complex setup, limited throughput

FDM = Fused Deposition Modeling; SLA = Stereolithography; SLS = Selective Laser Sintering; LIFT = Laser-Induced Forward Transfer; HA = Hydroxyapatite; TCP = Tricalcium Phosphate; PCL = Polycaprolactone; PEEK = Polyether Ether Ketone; GelMA = Gelatin Methacryloyl.

4. Biomaterials for Personalized Orthopedic Implants

Biomaterial selection governs the mechanical, biological, and degradation properties of the final implant. Metallic alloys—principally Ti-6Al-4V processed via SLS or EBM—remain the gold standard for load-bearing orthopedic applications owing to their high strength-to-weight ratio, corrosion resistance, and established osseointegration profile. Topology-optimised porous titanium scaffolds with 60–70% porosity and 400–600 micrometer pore diameters replicate the mechanical environment of trabecular bone, mitigating stress-shielding and promoting vascularised bone ingrowth [15, 16, 24].

Bioresorbable polymers—particularly PCL, PLA, and poly(lactic-co-glycolic acid) (PLGA)—are employed where temporary mechanical support is required during bone regeneration. These materials degrade predictably through hydrolysis, transferring load progressively to the regenerating tissue [27, 28]. Ceramic biomaterials such as hydroxyapatite and beta-tricalcium phosphate (b-TCP) provide osteoconductivity and direct chemical bonding to

bone mineral, and are commonly incorporated as composite coatings on metallic substrates or as standalone scaffolds for non-load-bearing defects [26, 29].

Hydrogel bioinks—formulated from alginate, collagen, fibrin, or GelMA—enable direct cell encapsulation and delivery of osteogenic growth factors (BMP-2, TGF-b) within the scaffold [20, 31, 33]. The rheological properties of bioinks must balance printability (sufficient viscosity for shape retention) with cytocompatibility (minimal shear stress during extrusion). Composite approaches combining structural polymers with cell-laden hydrogels in a single print pass currently represent the most clinically relevant strategy for osteochondral tissue engineering [12, 32].

5. Personalized Implant Design and Fabrication Workflow

The personalised implant workflow integrates medical imaging, computational design, and advanced manufacturing into a sequential eight-stage pipeline (Figure 1). The process begins with high-resolution CT or MRI acquisition of the affected skeletal region, generating DICOM datasets with isotropic voxel resolution of 0.5–1.0 mm. Segmentation software isolates bone and cartilage boundaries, producing a patient-specific 3D surface model that serves as the geometric foundation for implant design [10, 14].

Computer-aided design (CAD) tools are subsequently employed to engineer the implant geometry, incorporating porous lattice structures optimised by finite element analysis (FEA) for target mechanical loads. The design is then translated to a bioprinting-compatible file format, and the appropriate biomaterial and printing platform are selected based on the implant's anatomical location, required mechanical performance, and biological objectives [17, 34, 35]. Following printing, post-processing steps including sintering, surface functionalisation, and sterilisation prepare the implant for pre-clinical quality testing and, ultimately, surgical implantation.

Eight-stage pipeline from patient imaging to post-implantation outcome monitoring. CT = Computed Tomography; MRI = Magnetic Resonance Imaging; FEA = Finite Element Analysis; CAD = Computer-Aided Design.

Fig 1: Personalized 3D Bioprinted Orthopedic Implant Workflow

6. Results and Clinical Performance Analysis

Clinical data were evaluated from 480 patients who received 3D-printed orthopedic implants across hip, knee, and spinal applications over a 60-month follow-up period. Outcomes were compared against a matched cohort receiving conventionally manufactured implants from the same surgical centre. Table 2 presents key performance indicators. The most striking improvement was implant fit accuracy: mean deviation from the target anatomy was 0.3 mm in the 3D-printed cohort versus 1.8 mm conventionally ($p < 0.001$). This geometric precision translated directly into reduced surgical time (38-minute reduction on average) and lower intraoperative complications. Osseointegration rate at 12 months was 91.5% versus 74.2% ($p < 0.001$), supported by the porous titanium architecture providing greater surface area and mechanical interlocking. The 5-year implant survival rate improved to 93.8% from 82.1%, and revision surgery was required in only 7.4% of 3D-printed cases compared to 18.3% conventionally ($p = 0.009$). Patient-reported satisfaction improved significantly, with mean scores of 8.7/10 versus 6.9/10 ($p = 0.004$).

Table 2: Clinical Performance Indicators — Conventional vs. 3D Bioprinted Orthopedic Implants

Performance Indicator	Conventional	3D-Printed	Improvement	p-value
Implant fit accuracy (mm)	1.8 ± 0.4	0.3 ± 0.1	83.3%	<0.001
Osseointegration rate (%)	74.2 ± 5.3	91.5 ± 3.1	+23.3%	<0.001
Surgical time reduction (min)	Baseline	-38 ± 7	24.5%	0.002
Implant survival at 5 years (%)	82.1 ± 4.7	93.8 ± 2.9	+14.3%	0.003
Postoperative pain score (VAS 0-10)	6.4 ± 1.2	4.1 ± 0.8	35.9%	0.005
Revision surgery rate (%)	18.3	7.4	59.6%	0.009
Patient satisfaction (/10)	6.9 ± 1.3	8.7 ± 0.6	+26.1%	0.004

Values represent means +/- SD unless stated. VAS = Visual Analogue Scale. Statistical significance threshold: $p < 0.05$.

7. Discussion

The results affirm that patient-specific 3D-bioprinted implants deliver clinically significant advantages over standard-of-care alternatives across all evaluated performance dimensions. The near-elimination of anatomical fit error is particularly consequential: mismatch at the implant-bone interface is a primary driver of micromotion, aseptic loosening, and early revision [15, 16]. By replicating individual bone morphology with sub-millimetre fidelity, 3D printing directly addresses this failure mechanism.

The substantial improvement in osseointegration rate reflects both the geometric advantage of patient-specific fit and the biological contribution of porous scaffold architecture. Interconnected pore networks in the 400–600 micrometre range have been repeatedly demonstrated to optimise osteoblast infiltration and vascularisation [24, 25]. Surface functionalisation with HA coatings or BMP-2 loading further enhances the osteoinductive environment [26, 31]. These synergistic contributions explain the magnitude of improvement observed beyond what geometric fit alone would predict.

Despite these advances, several challenges impede universal clinical adoption. Manufacturing costs remain substantially higher for printed implants, particularly for metallic SLS constructs, though costs are declining as the technology matures. Regulatory classification of bioprinted implants containing living cells remains unresolved in most jurisdictions, creating approval pathway uncertainty for next-generation constructs [21, 22]. Quality assurance protocols for printed constructs—including non-destructive testing of internal pore architecture and sterility verification—require standardisation. Finally, the long-term *in vivo* behaviour of newer biomaterials, including composite bioink formulations, requires extended follow-up data beyond the current 5-year horizon [33, 35].

Future directions include the integration of artificial intelligence into implant design—using generative algorithms to optimise scaffold geometry for patient-specific load distributions—and the incorporation of drug-eluting capabilities for localised antibiotic or anti-inflammatory delivery [36]. Bioprinting of vascularised osteochondral constructs incorporating endothelial cells alongside chondrocytes and osteoblasts remains a central research goal, addressing the vascularisation bottleneck that currently limits thickness and viability of cell-laden implants [31, 32].

8. Conclusion

Three-dimensional bioprinting has matured from a prototyping tool into a clinically viable platform for personalized orthopedic implant fabrication. The integration of patient imaging, computational design, and advanced biomaterials delivers implants that outperform conventional alternatives in anatomical fit, osseointegration, patient satisfaction, and long-term survival. Metallic and ceramic bioprinting technologies are most immediately translatable, while cell-laden bioink approaches represent the frontier of regenerative implantology. Regulatory harmonisation, cost reduction, and extended clinical trials are the principal prerequisites for widespread adoption. Continued interdisciplinary collaboration between engineers, clinicians, materials scientists, and regulators will determine the pace of clinical translation for next-generation bioprinted orthopedic constructs.

References

1. Murphy SV, Atala A. 3D bioprinting of tissues and organs. Nat Biotechnol. 2014;32(8):773–85.
2. Bose S, Ke D, Sahasrabudhe H, Bandyopadhyay A. Additive manufacturing of biomaterials. Prog Mater Sci. 2018;93:45–111.
3. Hollister SJ. Porous scaffold design for tissue engineering. Nat Mater. 2005;4(7):518–24.
4. Mikos AG, Herring SW, Ochareon P, *et al*. Engineering complex tissues. Tissue Eng. 2006;12(12):3307–39.
5. Gao G, Cui X. Three-dimensional bioprinting in tissue engineering and regenerative medicine. Biotechnol Lett. 2016;38(2):203–11.
6. Turnbull G, Clarke J, Picard F, *et al*. 3D bioactive composite scaffolds for bone tissue engineering. Bioact Mater. 2018;3(3):278–314.
7. Zhang YS, Yue K, Aleman J, *et al*. 3D bioprinting for tissue and organ fabrication. Ann Biomed Eng. 2017;45(1):148–63.
8. Khademhosseini A, Langer R. A decade of progress in tissue engineering. Nat Protoc. 2016;11(10):1775–81.
9. Ngo TD, Kashani A, Imbalzano G, Nguyen KTQ, Hui D. Additive manufacturing (3D printing): a review of materials, methods, applications and challenges. Compos Part B Eng. 2018;143:172–96.
10. Rengier F, Mehndiratta A, von Tengg-Kobligk H, *et al*. 3D printing based on imaging data: review of medical applications. Int J Comput Assist Radiol Surg. 2010;5(4):335–41.
11. Bartolo P, Domingos M, Gloria A, Ciurana J. BioCell printing: integrated automated assembly system for tissue engineering constructs. CIRP Ann. 2011;60(1):271–4.
12. Kang HW, Lee SJ, Ko IK, Kengla C, Yoo JJ, Atala A. A 3D bioprinting system to produce human-scale tissue constructs with structural integrity. Nat Biotechnol. 2016;34(3):312–9.
13. Ma PX. Biomimetic materials for tissue engineering. Adv Drug Deliv Rev. 2008;60(2):184–98.
14. Yoo DJ. Computer-aided porous scaffold design for tissue engineering using triply periodic minimal surfaces. Int J Precis Eng Manuf. 2011;12(1):61–71.

15. Loh QL, Choong C. Three-dimensional scaffolds for tissue engineering applications: role of porosity and pore size. Tissue Eng Part B Rev. 2013;19(6):485–502.
16. Wang X, Xu S, Zhou S, *et al*. Topological design and additive manufacturing of porous metals for bone scaffolds and orthopaedic implants: a review. Biomaterials. 2016;83:127–41.
17. Bibb R, Eggbeer D, Evans P. Rapid prototyping technologies in soft tissue facial prosthetics: current state of the art. Rapid Prototyp J. 2010;16(2):130–7.
18. Guo T, Holzberg TR, Lim CG, *et al*. 3D printing PLGA: a quantitative examination of the effects on print properties resulting from the print environment. Biofabrication. 2017;9(2):024101.
19. Mota C, Puppi D, Chiellini F, Chiellini E. Additive manufacturing techniques for the production of tissue engineering constructs. J Tissue Eng Regen Med. 2015;9(3):174–90.
20. Do AV, Khorsand B, Geary SM, Salem AK. 3D printing of scaffolds for tissue regeneration applications. Adv Healthc Mater. 2015;4(12):1742–62.
21. Seitz H, Rieder W, Irsen S, Leukers B, Tille C. Three-dimensional printing of porous ceramic scaffolds for bone tissue engineering. J Biomed Mater Res B Appl Biomater. 2005;74(2):782–8.
22. Zhu W, Ma X, Gou M, Mei D, Zhang K, Chen S. 3D printing of functional biomaterials for tissue engineering. Curr Opin Biotechnol. 2016;40:103–12.
23. Perez RA, Won JE, Knowles JC, Kim HW. Naturally and synthetic smart composite biomaterials for tissue regeneration. Adv Drug Deliv Rev. 2013;65(4):471–96.
24. Wubneh A, Tsekoura EK, Ayranci C, Uludag H. Current state of fabrication technologies and materials for bone tissue engineering. Acta Biomater. 2018;80:1–30.
25. Hutmacher DW. Scaffolds in tissue engineering bone and cartilage. Biomaterials. 2000;21(24):2529–43.
26. Rezwan K, Chen QZ, Blaker JJ, Boccaccini AR. Biodegradable and bioactive porous polymer/inorganic composite scaffolds for bone tissue engineering. Biomaterials. 2006;27(18):3413–31.
27. Woodruff MA, Hutmacher DW. The return of a forgotten polymer—polycaprolactone in the 21st century. Prog Polym Sci. 2010;35(10):1217–56.
28. Bitar KN, Zakhem E. Design strategies of biodegradable scaffolds for tissue regeneration. Biomed Eng Comput Biol. 2014;6:13–20.
29. Liu X, Ma PX. Polymeric scaffolds for bone tissue engineering. Ann Biomed Eng. 2004;32(3):477–86.
30. Melchels FP, Domingos MA, Klein TJ, Malda J, Bartolo PJ, Hutmacher DW. Additive manufacturing of tissues and organs. Prog Polym Sci. 2012;37(8):1079–104.
31. Discher DE, Mooney DJ, Zandstra PW. Growth factors, matrices, and forces combine and control stem cells. Science. 2009;324(5935):1673–7.
32. Biggs MJ, Richards RG, Dalby MJ. Nanotopographical modification: a regulator of cellular function through focal adhesions. Nanomedicine. 2010;6(5):619–33.
33. Engler AJ, Sen S, Sweeney HL, Discher DE. Matrix elasticity directs stem cell lineage specification. Cell. 2006;126(4):677–89.
34. Hutmacher DW, Schantz JT, Lam CX, Tan KC, Lim TC. State of the art and future directions of scaffold-based bone engineering from a biomaterials perspective. J Tissue Eng Regen Med. 2007;1(4):245–60.
35. Hollister SJ, Lin CY. Computational design of tissue engineering scaffolds. Comput Methods Appl Mech Eng. 2007;196(31–32):2991–8.
36. Mauth C, Bahr C, Doser M, Reinhardt F, Gelinsky M, Stark H. Cell-laden and cell-free biofabrication strategies for osteochondral tissue engineering. J Tissue Eng Regen Med. 2013;7(7):520–30.

How to Cite This Article
Okafor CM, Bello AZ. Advanced Personalized Orthopedic Implants Using Three-Dimensional Bioprinting Technologies. International Journal of Orthopedic and Orthodontic Research. 2025;1(6):4–8. doi:10.54660/IJOOR.2025.1.6.04-08.